| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
k-80003 manufacturers
- K-80003
-
- $64.00
-
2026-07-27
- CAS:1292821-90-9
- Purity: 99.76%
- Supply Ability: 10g
- K-80003
-
- $64.00
-
2026-07-27
- CAS:1292821-90-9
- Purity: 99.76%
- Supply Ability: 10g
|
| | k-80003 Basic information |
| Product Name: | k-80003 | | Synonyms: | k-80003;K-80003 (TX-803);TX-803;1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(1-methylethyl)phenyl]methylene]-, (1Z)-;K 80003,K80003;K-80003, 10 mM in DMSO | | CAS: | 1292821-90-9 | | MF: | C22H21FO2 | | MW: | 336.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1292821-90-9.mol |  |
| | k-80003 Chemical Properties |
| Boiling point | 491.6±40.0 °C(Predicted) | | density | 1.192±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 30 mg/mL (89.18 mM) | | pka | 4.27±0.10(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | k-80003 Usage And Synthesis |
| Uses | K-80003 is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth. | | Definition | ChEBI: [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid is a sulindac-based non-steroidal anti-inflammatory drug. It has a role as a non-steroidal anti-inflammatory drug. It is functionally related to an acetic acid. | | in vivo | K-80003 is a potent inhibitor of AKT activation by all-trans-retinoic acid. K-80003 displays enhanced efficacy in inhibiting tRXRα-dependent AKT activation and tRXRα tumor growth in animals. K-80003 has high affinity to RXRα but lacks COX inhibitory activity[1]. | | References | [1] Zhou H, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73. DOI:10.1016/j.ccr.2010.04.023 [2] Chen L, et al. Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα. Nat Commun. 2017 Jul 17;8:16066. DOI:10.1038/ncomms16066 |
| | k-80003 Preparation Products And Raw materials |
|